Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/30299% above fair value
$144.85+0.51 (+0.35%)
Close on Oct 30, 2026Market cap $9.37BP/E 140.6Yield –
Earnings
Protagonist Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 5, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$213.50M
+3749.6% on a year earlier
EPS, Q2 FY2026
$2.29
-$0.55 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Protagonist Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026Expected | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026after the close | $213.50M | +3749.6% | $2.29 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026after the close | $56.40M | +99.3% | $0.05 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026after the close | $7.40M | -95.7% | -$0.69 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $4.70M | 0.0% | -$0.62 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025after the close | $5.55M | +32.0% | -$0.55 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 6, 2025after the close | $28.30M | -88.9% | -$0.19 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 21, 2025before the open | $170.64M | +184.4% | $1.98 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024after the close | $4.70M | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | $4.20M | – | -$0.50 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024after the close | $255.00M | – | $3.26 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024after the close | $60.00M | – | $0.44 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023after the close | – | – | -$0.58 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023after the close | – | – | -$0.68 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023after the close | – | – | -$0.67 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 15, 2023after the close | – | – | -$0.69 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022after the close | – | – | -$0.64 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022after the close | $900.00K | – | -$0.84 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022after the close | $25.70M | – | -$0.43 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022after the close | $8.60M | – | -$0.77 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021after the close | $10.30M | – | -$0.70 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 4, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 10, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020after the close | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Protagonist Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Protagonist Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Protagonist Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- News
- News
- News
- News
- News
- News
- Results